Graft Versus Host Disease (GVHD): Disease Overview

Graft versus host disease (GvHD) is a potentially life-threatening complication that can occur after a stem cell or bone marrow transplant from another person. During an allogeneic transplant, the donated stem cells from a donor recognize the recipient’s body as foreign and attack it.

This can lead to two types of GvHD: Acute and Chronic.

Acute GvHD:

Acute GvHD usually occurs within the first 100 days after the transplant and is characterized by an inflammatory reaction that affects the skin, gastrointestinal tract, and liver. Symptoms may include skin rash, diarrhea, abdominal pain, nausea, vomiting, and jaundice. Acute GvHD can be further classified into grades I-IV, depending on the severity of symptoms.

Chronic GvHD:

Chronic GVHD usually occurs after day 100 and can last for several months to years. It can affect multiple organs and may present with a variety of symptoms, such as skin rash, dry mouth, dry eyes, joint pain, fatigue, and weight loss. Chronic GvHD can also be classified into mild, moderate, or severe, based on the extent and severity of organ involvement.

Staging of GVHD:

To better manage and treat GvHD, it is important to stage the disease accurately. The most widely used staging system for acute GvHD is the Glucksberg criteria, which classifies the disease into four stages based on the severity of organ involvement and the degree of immunosuppression required for treatment. The National Institutes of Health (NIH) consensus criteria are commonly used to stage chronic GvHD and classify it into mild, moderate, or severe.

Treatment of GvHD:

The treatment of GvHD depends on the type, severity, and extent of organ involvement.  Treatment for GvHD includes drugs that suppress or calm the immune system, such as corticosteroids, calcineurin inhibitors, and monoclonal antibodies.

Mild cases of acute GvHD may be managed with topical or systemic corticosteroids, while severe cases may require additional immunosuppressive therapies, such as cyclosporine, tacrolimus, or anti-thymocyte globulin (ATG). Chronic GvHD is usually managed with a combination of corticosteroids and immunosuppressive agents.

Steroids are the mainstay of treatment for GvHD. However, some patients may not respond adequately to steroids, which is referred to as steroid refractory GvHD. In this condition, GvHD that does not improve with high doses of steroids (e.g., prednisone) or that progresses despite treatment with steroids.

On the other hand, some patients may respond initially to steroids but become dependent on them to control GVHD, which is referred to as steroid dependent GVHD. This means that reducing or stopping steroid treatment can cause GVHD symptoms to return.

Overall, steroid refractory and steroid dependent GVHD are challenging conditions that require careful management. The approach to both steroid-dependent and steroid-refractory GVHD is the same, which is to go to a second-line treatment (steroid free approaches).

Research is ongoing to improve the prevention and treatment of Steroid Refractory and Steroid Dependent GvHD. Some promising approaches include using mesenchymal stem cells, regulatory T cells, Extracorporeal photopheresis or other cell therapies to modulate the immune response and reduce inflammation.

Geography

• Technology covered: Worldwide
• Market covered:  USA, Europe and Japan

Time Period

• For technology coverage: 2020 till present
• For market analysis: 2023 till 2033

Graft Vs Host Disease non-steroidal treatments Report Key Strengths

• 10-Years Forecast
• Top players
• Treatments approach segmentation
• KOL analysis insights
• SWOT of treatments
• Opportunity (Licensees and suppliers)

• Highly Analysed Graft Vs Host Disease non-steroidal treatments Market

Graft Vs Host Disease non-steroidal treatments Report Assessment

• Current Graft Vs Host Disease non-steroidal treatments Practices
• Unmet Needs
• Approved Product Profiles
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• Therapeutic assessment of drugs

Graft Vs Host Disease non-steroidal treatments Market Report Highlights

• The Graft Versus Host disease market is expected to change over the next few years as a result of increased global healthcare spending and increased knowledge of the condition. This will increase the market’s size and allow pharmaceutical companies to extend their market share.
• Companies and academics working on Graft Versus Host Disease are evaluating obstacles and looking for opportunities that may have an impact on R&D. The focus of the currently being developed therapies is on cutting-edge methods to treat or ameliorate the disease state.
• The development of treatments for Graft Versus Host Disease is being done by companies. The market for therapy for Graft Versus Host Disease will be greatly impacted by the launch of new treatments.
• By identifying the general context of the research and development activities, our in-depth analysis of the pipeline assets at various stages of development (phase III and phase II), various emerging trends, comparative analysis of pipeline products with clinical profiles, kol’s , patent filing, launch date, and product development activities will assist the clients in making decisions regarding their drug delivery portfolio. 

Reasons to buy

• By comprehending the trends influencing and driving Graft Vs Host Disease non-steroidal treatment strategies, the report will aid in the development of business strategies.
• To comprehend the future market of Graft Vs Host Disease non-steroidal treatment, also market competition and to gain a thorough understanding of the major market drivers and obstacles.
• Finding strong opportunities in the market that will aid in the development of tactics for edging out rivals.
• Comprehension of how the market for Graft Vs Host Disease will be competitive in the future.
• Detailed patent examination to look for novelty in drug delivery techniques for Graft Vs Host Disease non-steroidal treatments

In order to give the most precise estimations and forecasts, Wissen Research uses an extensive and iterative research approach that is focused on reducing deviation. The company blends top-down and bottom-up methodologies for market segmentation and quantitative estimation. In addition, data triangulation, which examines the market from three separate angles, is a recurrent topic present in all of our research studies. Important components of the approach used for all of our studies include the following.:

Preliminary data mining

On a wide scale, unprocessed market data is collected. Continuous data filtering makes sure that only verified and authenticated sources are taken into account. Additionally, data is extracted from a wide range of reports in our repository and from a number of reputable premium databases. We gather information from raw material suppliers, distributors, and purchasers to help with this since understanding the entire value chain is crucial for a thorough understanding of the market.

Surveys, technical symposia, and trade magazines are used to gather information on technical concerns and trends. Technical information focusing on white space and freedom of movement is also obtained from an intellectual property standpoint. Additionally, information on the industry’s drivers, constraints, and pricing patterns is obtained. As a result, a variety of original data are included in the material that is then cross-validated and certified with published sources

Statistical model

We use simulation models to generate our market projections and estimates. Every study receives a special model that is tailored to it. Data for market dynamics, the technology environment, application development, and pricing patterns are gathered and supplied into the model all at once for analysis. The relative relevance of these factors is investigated, and their impact on the forecast period is assessed, using correlation, regression, and time series analysis. The process of market forecasting combines technological analysis with economic strategies, practical business acumen, and subject expertise.

Econometric models are frequently used for short-term forecasting, but technology market models are typically employed for long-term forecasting. These are based on a confluence of the business environment, regulatory environment, economic projection, and technical landscape. In order to develop global estimates, it is preferable to estimate markets from the bottom up by integrating data from key regional markets. This is required to ensure accuracy and a complete comprehension of the subject. Among the variables taken into account for forecasting are:

• Market drivers and restraints, as well as the current and anticipated effects of each

   scenario for raw materials and supply versus pricing patterns

 Regulations and anticipated developments

• Present capacity and anticipated capacity growth to 2033

We give these criteria weights and use weighted average analysis to assess their market influence in order to calculate the anticipated market growth rate.

Data Collection Matrix

Table of Contents

1. EXECUTIVE SUMMARY

1.1          Overview of the GVHD Treatment Market

1.2          Key Trends and Developments in Steroid-Free GVHD Treatments

1.3          Market Size and Growth Projections

1.4          Technology Competitive Landscape

2. INTRODUCTION

2.1          Scope

2.2          Objective of the Study

2.3          Technology Categorization

2.4          Inclusion/Exclusion

3. OVERVIEW

3.1          Graft Versus Host Disease (GVHD): Disease Overview

3.2          Historic Period

3.3          Epidemiology

3.4          Current Treatments

4. NON-STEROIDAL TREATMENTS OF GVHD: PATENT ANALYSIS

4.1          Overview of Major Treatment Approaches for Steroid-Free GVHD Treatments 

4.1.1      Top Assignee

4.1.2      Geography focus of top Assignees           

4.1.3      Legal Status       

4.1.4      Geography        

4.1.5      Assignee Segmentation

4.1.6      Network analysis of the top collaborating entities in Non-Steroidal GVHD treatments patent applications

4.1.7      Technology Evolution    

4.1.8      Key Patents

4.1.9      Application trend

4.1.10    Application and Issued Trend

4.1.11    Key technology

4.2          Subclasses of Each Treatment Approach

4.2.1      Biologics

4.2.2      Small molecules              

4.2.3      Therapy

4.2.4      Others

4.3          Strengths, Weaknesses, Opportunities and Threats of Each Technology Approach

5              NON-STEROIDAL TREATMENTS OF GVHD: SCIENTIFIC LITERATURE ANALYSIS

5.1          Publication Trends

5.1.1      Filing Trend

5.1.2      Treatments by top applicants w.r.t year

5.1.3      Geography of Applicants

5.2          Key opinion leader Analysis-Insights

5.3          Research focus areas

5.3.1      Transplant type

5.3.2      Graft type

5.3.3      Specific condition (Refractory or Resistant)

5.3.4      Disease Type

5.3.5      Therapeutic Approaches

5.3.6      Treatment Type

5.3.7      Organs Affected

6              NON-STEROIDAL TREATMENTS OF GVHD: PRODUCT ANALYSIS

6.1          Overview of products in the steroid-free GVHD treatment market

6.2          Drug Chapter

6.2.1      Approved drugs

6.2.2      Pipeline drugs

6.3          Company profiles, product portfolios

6.4          Emerging products

6.5          Strategic Activities (Collaboration, Acquisitions, New launches and Licensing)

6.6          Therapeutic Assessment of Drugs

6.6.1      Assessment by Product Type

6.6.2      Assessment by Mechanism of Action

6.6.3      Assessment by Route of Administration

6.6.4      Assessment by Stage and Route of Administration

6.6.5      Assessment by Molecule Type

6.6.6      Assessment by Stage and Molecule Type

7              NON-STEROIDAL TREATMENTS OF GVHD: CLINICAL TRIAL ANALYSIS

7.1          Chapter Overview

7.2          Analysis by Trial Registration Year

7.3          Analysis by Phase of Development

7.4          Analysis by Number of Patients Enrolled

7.5          Analysis by Status of Trial

7.6          Analysis by Study Design

7.7          Analysis by Type of Product

7.8          Analysis by Geography

7.9          Analysis by Key Sponsors / Collaborators

8. NON-STEROIDAL TREATMENTS OF GVHD: OPPORTUNITY ANALYSIS

8.1          Potential Licensees for GVHD Non-Steroidal Drugs

8.2          Geography of Suppliers

8.3          Opportunity of Treatments/Drugs in Different Countries

9              NON-STEROIDAL TREATMENTS OF GVHD: REGULATORY ANALYSIS

9.1          FDA Approval Process for GVHD Treatments

9.2          Regional regulatory frameworks and market entry barriers

10           NON-STEROIDAL TREATMENTS OF GVHD: MARKET ANALYSIS

10.1        Chapter Overview

10.2        Methodology and Key Assumptions

10.3        Overall Steroid Refractory Graft-Versus-Host Disease Market, 2022-2033 (USD Million)

10.3.1    Global Steroid Refractory Graft-versus-Host Disease Market: Distribution by Drug Sales, 2022-2033 (USD Million)

10.3.1.1 Global Steroid Refractory GvHD: Distribution by Rezurock Sales, 2022-2033 (USD Million)

10.3.1.2 Global Steroid Refractory GvHD Market: Distribution by Jakafi Sales, 2022-2033 (USD Million)

10.3.1.3 Global Steroid Refractory GvHD Market: Distribution by Ibrutinib Sales, 2022-2033 (USD Million)               

10.3.1.4 Global Steroid Refractory GvHD Market: Distribution by Remestemcel-L Sales, 2023-2033 (USD Million)

10.3.1.5 Global Steroid Refractory GvHD Market: Distribution by MaaT013 Sales, 2025-2033 (USD Million)               

10.3.2    Global Steroid Refractory Graft-Versus-Host Disease Market: Distribution by Type of GvHD, 2022-2033 (USD Million)

10.3.2.1 Global Steroid Refractory GvHD Market: Distribution by Acute GvHD, 2022-2033 (USD Million)

10.3.2.2 Global Steroid Refractory GvHD Market: Distribution by Chronic GvHD, 2022-2033 (USD Million)

10.3.3    Global Steroid Refractory Graft-Versus-Host Disease Market: Distribution by Route of Administration, 2022-2033 (USD Million)

10.3.3.1 Global Steroid Refractory GvHD Market: Distribution by Oral Route of Administration, 2022-2033 (USD Million)     

10.3.3.2 Global Steroid Refractory GvHD Market: Distribution by Intravenous Route of Administration, 2022-2033 (USD Million)          

10.3.3.3 Global Steroid Refractory GvHD Market: Distribution by Rectal Route of Administration, 2022-2033 (USD Million)     

10.3.4    Global Steroid Refractory Graft-Versus-Host Disease Market: Distribution by End-User, 2022-2033 (USD Million)

10.3.4.1 Global Steroid Refractory GvHD Market: Distribution by Adult Patients, 2022-2033 (USD Million)

10.3.4.2 Global Steroid Refractory GvHD Market: Distribution by Pediatric Patients, 2022-2033 (USD Million)

10.3.5    Global Steroid Refractory Graft-Versus-Host Disease Market: Distribution by Key Geographical Regions, 2022-2033 (USD Million)             

10.3.5.1 Global Steroid Refractory GvHD Market in US, 2022-2033 (USD Million)

10.3.5.2 Global Steroid Refractory GvHD Market in Europe, 2022-2033 (USD Million)

10.3.5.3 Global Steroid Refractory GvHD Market in Japan, 2022-2033 (USD Million)

11. Non-Steroidal Treatments of GVHD: Future Outlook

11.1        Emerging Trends

11.2        Growth Opportunities

11.3        Challenges and Risks     

12. Appendix

List of Figures

List of Graphs

List of tables